Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model
Publication
, Conference
Reese, E; Hjelmeland, A; McLendon, R; Holland, E; Bigner, D; Wang, X; Rich, J
Published in: NEURO-ONCOLOGY
July 1, 2005
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
301 / 301
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Reese, E., Hjelmeland, A., McLendon, R., Holland, E., Bigner, D., Wang, X., & Rich, J. (2005). Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model. In NEURO-ONCOLOGY (Vol. 7, pp. 301–301). Edinburgh, SCOTLAND: DUKE UNIV PRESS.
Reese, E., A. Hjelmeland, R. McLendon, E. Holland, D. Bigner, X. Wang, and J. Rich. “Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model.” In NEURO-ONCOLOGY, 7:301–301. DUKE UNIV PRESS, 2005.
Reese E, Hjelmeland A, McLendon R, Holland E, Bigner D, Wang X, et al. Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 301–301.
Reese, E., et al. “Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model.” NEURO-ONCOLOGY, vol. 7, no. 3, DUKE UNIV PRESS, 2005, pp. 301–301.
Reese E, Hjelmeland A, McLendon R, Holland E, Bigner D, Wang X, Rich J. Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 301–301.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
301 / 301
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences